PARTI . We are a clinical-stage pharmaceutical company developing a novel class of medicines, which we refer to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, makingBicycle moleculesattractive candidates for drug development.Bicycle molecules are a unique ther...
Q2 FY2026 — expected 2026-09-09
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | BCYC | discussed_in_filing Cybersecurity | |
| topic_mention | BCYC | discussed_in_filing Trusted Computing | |
| topic_mention | BCYC | discussed_in_filing Blockchain & Crypto | |
| topic_mention | BCYC | discussed_in_filing Regulation | |
| topic_mention | BCYC | discussed_in_filing Healthcare & Bio | |
| topic_mention | BCYC | discussed_in_filing Platform & Ecosystem | |
| topic_mention | BCYC | discussed_in_filing Cybersecurity | |
| topic_mention | BCYC | discussed_in_filing Trusted Computing | |
| topic_mention | BCYC | discussed_in_filing Blockchain & Crypto | |
| topic_mention | BCYC | discussed_in_filing Regulation | |
| topic_mention | BCYC | discussed_in_filing Healthcare & Bio | |
| topic_mention | BCYC | discussed_in_filing Platform & Ecosystem | |
| topic_mention | BCYC | discussed_in_filing Cybersecurity | |
| topic_mention | BCYC | discussed_in_filing Trusted Computing | |
| topic_mention | BCYC | discussed_in_filing Blockchain & Crypto | |
| topic_mention | BCYC | discussed_in_filing Regulation | |
| topic_mention | BCYC | discussed_in_filing Healthcare & Bio | |
| topic_mention | BCYC | discussed_in_filing Platform & Ecosystem | |
| topic_mention | BCYC | discussed_in_filing Cybersecurity | |
| topic_mention | BCYC | discussed_in_filing Trusted Computing |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-17 | 2025-12-31 | 0001104659-26-028971 | EDGAR | 118K words |
| 2025-02-25 | 2024-12-31 | 0001558370-25-001438 | EDGAR | — |
| 2024-02-20 | 2023-12-31 | 0001558370-24-001324 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0001558370-23-002238 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001558370-22-002457 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001558370-21-002758 | EDGAR | — |
| 2020-03-10 | 2019-12-31 | 0001558370-20-002278 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-30 | 2025-09-30 | 0001104659-25-104010 | EDGAR | 71K words |
| 2025-08-08 | 2025-06-30 | 0001558370-25-010843 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0001558370-25-006049 | EDGAR | — |
| 2024-10-31 | 2024-09-30 | 0001558370-24-014004 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001558370-24-010949 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0001558370-24-006453 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001558370-23-017317 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001558370-23-013057 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001558370-23-007979 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001558370-22-016140 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001558370-22-012050 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001558370-22-007223 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-17 | 0001104659-26-028954 | EDGAR | 4K words |
| 2026-02-03 | 0001104659-26-009501 | EDGAR | — |
| 2026-01-12 | 0001104659-26-002706 | EDGAR | — |
| 2025-10-30 | 0001104659-25-104004 | EDGAR | — |
| 2025-09-08 | 0001104659-25-088238 | EDGAR | — |
| 2025-08-08 | 0001104659-25-075435 | EDGAR | — |
| 2025-06-17 | 0001104659-25-060316 | EDGAR | — |
| 2025-05-01 | 0001104659-25-043014 | EDGAR | — |
| 2025-04-29 | 0001104659-25-040625 | EDGAR | — |
| 2025-03-27 | 0001104659-25-028531 | EDGAR | — |
132 total filings indexed. 103 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001761612 |
| Ticker | BCYC |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | X0 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report